

SARS-CoV-2 Vaccination and Solid Organ Transplant Patients: Data Needed to Inform Safety and Efficacy

Michael G. Ison, MD, MS,^{1,2} Robin Avery, MD,³ Emily Blumberg, MD,⁴ Peter Chin-Hong, MD,⁵ Natasha Halasa, MD, MPH,⁶ Dan Kaul, MD,⁷ Steve Pergam, MD, MPH,^{8,9} Nicole M. Theodoropoulos, MD, MS,¹⁰ and Cameron R. Wolfe, MBBS, MPH¹¹

Solid organ transplant (SOT) recipients appear to have higher rates of mortality from COVID-19 when compared with other populations, attributed to underlying immunosuppression and concomitant comorbidities.¹ Such findings are consistent with other respiratory viral infections that are associated with an increased risk of morbidity and mortality in immunocompromised hosts.²

Further, these patients experience prolonged SARS-CoV-2 shedding, which has been linked to emergence of viral mutants. Prolonged shedding also poses a risk of transmission and requires prolonged isolation, potentially leading to delays in medical care.

Although use of various SARS-CoV-2 vaccines is being considered for these at-risk patients, SOT recipients were specifically excluded from the completed and most ongoing vaccine trials. We expect that vaccine responses in these patients may be significantly impaired due to both their primary underlying comorbid conditions and immunosuppressive medications, as has been seen with other vaccines in this population.³

The candidate vaccines against SARS-CoV-2 use novel mechanisms to elicit immune responses, including mRNA and viral vectors. The safety of these vaccines has not been established in immunocompromised patients. Historically, vaccines can induce donor-specific and non-donor-specific antibodies but have not been associated with graft rejection in SOT patients.³ How frequently donor-specific antibodies develop after SARS-CoV-2 vaccination and whether or not these antibodies may increase the risk of allograft dysfunction is unknown. Emerging protein-based vaccines use adjuvants that have not been widely studied in transplant recipients and also raise theoretical concerns for possible graft rejection. Although most studies of adjuvanted vaccines have not shown an increased risk of rejection, boosting of anti-HLA antibodies might occur.³ Given the rapid uptake of vaccine proteins throughout the body, we would anticipate that any significant upregulation of the immune response might occur within the first few weeks, as seen in the published data from completed trials, allowing us to promptly identify if rejection might occur at increased rates after vaccination.^{4,5} Understanding these unique safety issues will likely build confidence in these vaccines for providers and patients.

There, too, is an urgent need to fund prospective studies to define the efficacy of the SARS-CoV-2 vaccine in SOT recipients. The immunogenicity, persistence of antibody titers, clinical efficacy data, and unique adverse events need to be understood for SOT patients. The specific impact and appropriate timing of vaccine in patients chronically on costimulatory blockers and B cell-active therapies, like rituximab, merit additional study. Efficacy must be understood in terms of prevention of infection, hospitalization, and death, as well as the reduction of SOT recipients' role in community spread. As these vaccines have different mechanisms of action, comparison of relative safety and humoral and cellular immune

Received 2 February 2021. Revision received 19 February 2021.

Accepted 21 February 2021.

¹ Divisions of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL.

² Division of Organ Transplantation, Northwestern University Feinberg School of Medicine, Chicago, IL.

³ Division of Infectious Diseases, Johns Hopkins University, Baltimore, MD.

⁴ Division of Infectious Diseases, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.

⁵ Division of Infectious Diseases, University of California, San Francisco, San Francisco, CA.

⁶ Division of Pediatric Infectious Diseases, Vanderbilt University, Nashville, TN.

⁷ Division of Infectious Diseases, University of Michigan, Ann Arbor, MI.

⁸ Vaccine and Infectious Diseases Division, Fred Hutch Cancer Research Center, Seattle, WA.

⁹ Division of Infectious Diseases, University of Washington, Seattle, WA.

¹⁰ Division of Infectious Diseases, University of Massachusetts Medical School, Worcester, MA.

¹¹ Division of Infectious Diseases, Duke University, Durham, NC.

M.G.I., R.V., E.B., P.C.-H., N.H., D.K., S.P., N.M.T., and C.R.W. participated in the writing and revising of the article.

M.G.I. received research support, paid to Northwestern University, from AiCuris, Janssen, and Shire; he is a paid consultant for Adagio, AlloVir, Celltrion, Cidara, Genentech, Roche, Janssen, Shionogi, and Viracor Eurofins; he is also a paid member of DSMBs from Janssen, Merck, SAB Biotherapeutics, Sequiris, Takeda, and Vitearis. R.A. received research support, paid to Johns Hopkins University, from Aicuris, Astellas, Chimerix, Merck, Oxford Immunotec, Qiagen, and Takeda/Shire. E.B. received research support, paid to the University of Pennsylvania, from Merck and Takeda and has served on DSMB for Amlyx and has served as an unpaid scientific advisor for Merck and Takeda. D.K. received research support, paid to the University of Michigan, from AstraZenica and Janssen. S.P. has participated in clinical trials with Chimerix and Merck and receives research support from Global Life Technologies. N.M.T. received research support, paid to UMass Memorial Medical Center, from Incyte. C.R.W. is a paid consultant for Enzychem; he is also member of DSMBs from Atea and Biogen. The other authors declare no conflicts of interest.

Correspondence: Michael G. Ison, MD, MS, Division of Infectious Diseases, 645N Michigan Ave Suite 900, Chicago, IL 60611. (mgison@northwestern.edu).

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

ISSN: 0041-1337/21/10510-e131

DOI: 10.1097/TP.00000000000003747

efficacy of these vaccines will inform appropriate dosing regimens and shape vaccine approaches for future pandemics.^{4,5} Given the growing numbers of immunosuppressed and their potential to spread infection, understanding how best to implement SARS-CoV-2 immunization in SOT will enhance our ability to protect those at greatest risk for COVID-19 and ultimately our entire community.

REFERENCES

1. Azzi Y, Bartash R, Scalea J, et al. COVID-19 and solid organ transplantation: a review article. *Transplantation*. 2021;105:37–55.
2. Ison MG, Hirsch HH. Community-acquired respiratory viruses in transplant patients: diversity, impact, unmet clinical needs. *Clin Microbiol Rev*. 2019;32:e00042-19.
3. Haddadin Z, Krueger K, Thomas LD, et al. Alternative strategies of posttransplant influenza vaccination in adult solid organ transplant recipients. *Am J Transplant*. 2021;21:938–949.
4. Polack FP, Thomas SJ, Kitchin N, et al; C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *N Engl J Med*. 2020;383:2603–2615.
5. Voysey M, Clemens SAC, Madhi SA, et al; Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *Lancet*. 2021;397:99–111.